Lexaria Bioscience (CSE:LXX-OTCQX: LXRP) CEO Chris Bunka joined Steve Darling from Proactive in Vancouver to discuss the company commencing a program, in collaboration with leading laboratories in Canada and the U.S. to study the benefits of DehydraTECH in the fight against coronavirus disease COVID-19.
Bunka telling Proactive about that technology and why it may be effective, in the way it delivers fat-soluble drugs into the bloodstream.
CSE:LXX
Market: CSE
Market Cap: $33.9 m
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HEREDeep dive
Lexaria Bioscience is seeing increased demand for its DehydraTECH drug...
Most read
Buds & Duds: Cannabis stocks hold steady; Lexaria rises on amended agreement...
The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada, inched 0.2% higher at 122.9 points. Elsewhere, the OTCQX Cannabis index lost 0.2% to 489.3 points. Buds today are Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP), Curaleaf Holdings Inc...
on 01/22/2020
2 min read
Prev article
2 min read